Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy.

ABSTRACT: Cirrhosis is a leading cause of morbidity and mortality, impacting more than 120 million people worldwide. Although geographic differences exist, etiologic factors such as alcohol use disorder, chronic viral hepatitis infections, and non-alcoholic fatty liver disease are prevalent in nearly every region. Historically, significant effort has been devoted to modifying these risks to prevent disease progression. Nevertheless, more than 11% of patients with compensated cirrhosis experience hepatic decompensation each year. This transition signifies the most important prognostic factor in the natural history of the disease, corresponding to a decline in median survival to below 2 years. Over the past decade, the need for pharmacotherapies aimed at reducing the risk for hepatic decompensation ha

SUBMITTER: Lee S 

PROVIDER: S-EPMC9850948 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature